Indoco Remedies Limited · NSE:INDOCO
Indoco Remedies — Investor Presentation (March 2025)
33 slides from Indoco Remedies's investor presentation, March 2025
Slide 1: Investor Presentation March 2025
ndoco Remedies Limited N V E S T O R P R E S E N TAT I O N arch 2025
Slide 2: Snapshot
SNAPSHOT 7 Decades 11 Manufacturing EMPLOYEE of Presence in Facilities STRENGTH >6000 India 7 FDF Plants 4 API Plants R&D Facility (400+ Ranked 32nd Footprint (IQVIA MAT Feb’25) scientists) Ranked 22 nd Development of complex across 55+ in RX Report ophthalmic & injectables countries NDDS & New Plat
Slide 3: Company Overview
COMPANY OVERVIEW
Slide 4: Company Overview
C O M PA N Y OV E R V I E W • In 1945, our founder, Late Mr. Govind Ramnath Kare founded CONSOLIDATED REVENUE (INR Mn) & EBITDA ‘Indo-Continental Trading Company’, the principal MARGINS (%) business of which was to import pharmaceutical formulations 17,620 16,381 from Europe and distribute them in t
Slide 5: Board of Directors
B OA R D O F D I R E C T O R S Mr. Suresh G. Kare : Ms. Aditi Kare Panandikar : Chairman Mr. Suresh G. Kare, Chairman of Indoco Remedies Ltd., has been at the Managing Ms. Aditi Kare Director Panandikar, the Managing Director at Indoco, is a third- helm of the Company's affairs for over 60 years. Un
Slide 6: Key Management Personnel
KEY MANAGEMENT PERSONNEL Mr. Suresh G. Kare : Chairman Mr. Suresh G. Kare, Chairman of Indoco Remedies Ltd., has been at the helm of the Company's affairs for over 60 years. Under his able leadership, the Company has transformed into the fully integrated, research oriented pharma organization, that
Slide 7: Key Milestones
KEY MILESTONES 2019 – till date • USFDA successfully completes inspection at Indoco’s API Kilo Lab manufacturing facility and IAS division without any observations 2009 - 2018 • Warren Remedies Private Limited, a wholly owned • New API subsidiary of Indoco Remedies commences commercial 1999 - 2008 m
Slide 8: Geographical Footprint
GEOGRAPHICAL FOOTPRINT Baddi, Himachal Pradesh (2) Canada UK Belarus Netherlands Germany Poland France Ukraine Italy USA Spain Iraq Portugal Iran Lebanon Kuwait JordanBahrain Libya Algeria Egypt Qatar UAE Saudi Arabia Myanmar Taiwan Maurita Mali Oman nia Senegal NigerChad Yemen Thailand Waluj, Costa
Slide 9: Manufacturing Plants - Formulations
M A N U FA C T U R I N G P L A N T S - F O R M U L AT I O N S Dosages manufactured Solid Orals (Tablets Coated / Uncoated) Dosages manufactured Liquid Orals Solid Orals (Tablets) Creams & Ointments Liquid Orals Capsules (Hard Gelatin) External Preparations (Creams & Approved by UK-MHRA, TGA-Australi
Slide 10: Manufacturing Plants - Active Pharmaceutical Ingredients (API)
M A N U FA C T U R I N G P L A N T S – A C T I V E P H A R M A C U T I C A L I N G R E D I E N T S ( A P I ) API Plant I - Rabale API Plant II Kilolab - API Plant III - API Plant - Warren, Rabale Patalganga Aurangabad • Medium volume multipurpose • Small volume and high value • Medium and High-volum
Slide 11: State-of-the-Art R&D Center at Rabale, Navi Mumbai
S TAT E - O F -T H E - A R T R & D C E N T E R AT R A B A L E , N A V I M U M B A I R&D AS A PERCENTAGE OF SALES 1200 972 9.9% 1000 746 810 7.9% 800 600 586 5.9% 5.5% 400 5.0% 4.9% 4.7% 3.9% 200 1.9% 0 -0.1% FY22 FY23 FY24 9M-FY25 R&D (INR Mn) as a percentage of sales Formulation R&D Focus: • Comple
Slide 12: Awards and Accolades
AWA R D S A N D A C C O L A D E S Indoco Remedies Wins SAP ACE AWARD 2023 in the ‘Three Star Export House’ Lead 50 (NEXT) Supply ‘Game Changer’ category Accreditation 'Best-In-Class Supply Chain Chain Award Strategy and Design' Award at PHARMACONNECT 2025 Excellence in Pharma Excellence in Anti- IND
Slide 13: Business Overview
BUSINESS OVERVIEW
Slide 14: Business Segments
B U S I N E SS S E G M E N T S DOMESTIC INTERNATIO ACTIVE PHARMA ALLIED FORMULATIO NAL INGREDIENTS SERVICES N FORMULATIO N 57% 34% 8% 1% Branded Generics Regulated Markets - Active Pharma AnaCipher CRO Acute – 52% CRAMS for Generic Ingredients (APIs) for BA / BE Studies. Sub-Chronic – 34% Companies
Slide 15: Domestic Formulation Business
D O M E S T I C F O R M U L AT I O N B U S I N E SS • Indoco has a strong presence in the Indian formulations catering to both DOMESTIC FORMULATION SALES (INR Mn) acute and chronic therapies. 8,449 • The company is ranked 32nd in (MAT Feb’25) and 22nd in Rx (MAT Jan’25) as per IQVIA. 8,031 7,967 • I
Slide 16: Domestic Formulation: Top Brands
D O M E S T I C F O R M U L AT I O N : T O P B R A N D S TOP BRANDS AND MARKET SHARE THERAPEUTIC SEGMENT GYNAEC.; 1% 200 BLOOD RELATED; 1% CARDIAC; 0% 181 180 PAIN / ANALGESICS; 3% VITAMINS/ ANTI DIABETIC; 2% STOMATOLOGICA 160 51% 48% MINERALS/ LS; 18% NUTRIENTS; 5% 140 DERMA; 6% 120 111 109 OPHTHAL
Slide 17: International Formulation Business
I N T E R N AT I O N A L F O R M U L AT I O N B U S I N E SS INTERNATIONAL FORMULATION SALES (INR Mn) • Indoco’s International Business is spread across both emerging and regulated markets, including United States of America, Europe, Australia, New Zealand. 7,537 7,633 • It offers a complete solutio
Slide 18: Acquired 85% in Florida Pharmaceutical to Establish Front-end in USA
A C Q U I R E D 8 5 % I N F LO R I D A PHARMACEUTICAL T O E S TA B L I S H F R O N T- E N D I N T H E USA • On Jun 6 2023, Indoco Remedies acquired 85% of equity stake of the US based Florida Pharmaceutical Products Holding Company, LLC (“FPP”) for $4 Million from Contract Pharmacal Corp. • FPP is b
Slide 19: Active Pharmaceutical Ingredients (API)
ACTIVE PHARMACEUTICAL INGREDIENTS (API) • Indoco offers full range of services with respect to API supplies in API SALES (INR Mn) Regulated markets. 1,400 1,265 • The distinct advantage of API business emanates from the backward 1,200 integration for its own ANDAs and Dossiers as well. 1,000 892 800
Slide 20: Allied Services
ALLIED SERVICES Services Services • BA/BE studies Expertise, transparency, speed, and uncompromised quality are at • Healthy Male & Female the core of our operations, so we deliver value to our customers. Subjects Each of our verticals is operated by experts in their respective fields, • Regulatory
Slide 21: Strategic Overview
STRATEGIC OVERVIEW
Slide 22: Strategies Undertaken
S T R AT E G I E S U N D E RTA K E N Significant Capex undertaken over last 5 years to cater to future growth strategies for next 2-3 years without any major incremental capex requirement 27% 5-year CAGR in International Acquired Florida Pharmaceutical in USA to have a Revenues direct presence in US
Slide 23: Future Growth Strategies
F U T U R E G R O W T H S T R AT E G I E S • Expand in Northern and Eastern regions • Exploring options to strategic in-licensing in chronic segment • Focusing on sales force effectiveness, new product launches, exploring new channels of distribution and increasing our potential • Focus on brand bui
Slide 24: Environment
ENVIRONMENT E • Encouraging SLS and Paraben free products - Sensodent K and Sensodent KF range of products • Indoco acquired 26% stake each in Kanakal Wind Energy Private Limited and Jalansar Wind Energy Private Limited, for setting up Solar Power plants at Akkalkot, Solapur District in Maharashtra
Slide 25: Social
SOCIAL S Sanitatio n Environme nt Education Health Infrastructu re At Indoco, we believe that our success is deeply intertwined with the well-being and progress of the communities we serve. We are committed to create a positive and lasting impact on the society. Over the past year, we have made sign
Slide 26: Governance
G OV E R N A N C E G • Indoco has adopted transparency, disclosure, Transpare ncy accountability and ethics as its business practices. The management believes that these principles will enable it to achieve the long-term objectives and goals. • As part of its Corporate Governance philosophy, Disclos
Slide 27: Financial Overview
FINANCIAL OVERVIEW
Slide 28: Historical Standalone Financial Performance
H I S T O R I C A L S TA N D A L O N E F I N A N C I A L P E R F O R M A N C E PARTICULARS (INR Mn) FY22 FY23 FY24 9M-FY25 Operational Revenue 15,027 16,381 17,620 11,537 Operating Expenses 12,127 13,818 15,328 10,464 EBITDA 3,270 2,849 2,580 1,246 EBITDA Margin (%) 21.8% 17.4% 14.6% 10.8% Depreciat
Slide 29: Historical Standalone Balance Sheet
H I S T O R I C A L S TA N D A LO N E B A L A N C E S H E E T PARTICULARS (INR Mn) FY23 FY24 H1-FY25 PARTICULARS (INR Mn) FY23 FY24 H1-FY25 EQUITY 10,270 11,266 11,416 NON-CURRENT ASSETS 8,472 10,604 12,247 Equity Share Capital 184 184 184 a) Property, Plant and Equipment 5,785 6,197 6,340 Other Equ
Slide 30: Historical Financial Highlights
HISTORICAL FINANCIAL HIGHLIGHTS OPERATIONAL REVENUE EBIDTA (INR Mn) & PAT (INR Mn) & PAT (INR Mn) EBITDA MARGINS (%) MARGINS (%) 3,270 17,620 1,545 16,381 2,849 1,414 15,027 2,580 11,537 1,166 1,246 21.8% 17.4% 14.6% 175 10.3% 8.6% 6.6% 10.8% FY22 FY23 FY24 9M-FY25 FY22 FY23 FY24 9M-FY25 FY22 FY23 F
Slide 31: Capital Market Information
C A P I TA L M A R K E T I N F O R M AT I O N 30.00% SHARE PRICE PERFORMANCE 20.00% 10.00% 0.00% -10.00% -20.00% -30.00% Jan-24 Jan-24 Jan-24 Jan-24 Jan-24 Jan-24 Jan-24 Jan-24 Jan-24 Jan-24 Jan-24 Jan-24 Jan-24 Jan-24 Jan-24 Jan-24 Jan-24 Jan-24 Jan-24 Jan-24 Jan-24 Jan-24 Feb-24 Feb-24 Feb-24 Feb-
Slide 32: Disclaimer
DISCLAIMER Indoco Remedies Limited Disclaimer: No representation or warranty, express or implied, is made as to, and no reliance should be placed on the fairness, accuracy, completeness or correctness of the information or opinions contained in this presentation. Such information and opinions are in
Slide 33: Thank You
THANK YOU